<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02645734</url>
  </required_header>
  <id_info>
    <org_study_id>93210</org_study_id>
    <nct_id>NCT02645734</nct_id>
  </id_info>
  <brief_title>The Effect of Bevacizumab and Ziv-aflibercept in Diabetic Macular Edema</brief_title>
  <official_title>The Comparison Between the Therapeutic Effect of Intravitreal Bevacizumab and Ziv-aflibercept in Diabetic Macular Edema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shahid Beheshti University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shahid Beheshti University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this double clinical trial 132 patient with the history of DME (Diabetic Macular Edema) to
      receive intravitreous bevacizumab at a dose of 1.25mg (44 patient) , ziv-aflibercept at dose
      of 1.25 mg (44 patient) , ziv-aflibercept at dose of 2.5 mg (44 patient) .

      The study drugs were administered as often as every 4 weeks for 3 months.monitoring of
      best-corrected visual acuity, CST ( Central Subfield Thickness) by OCT (Optical coherence
      tomography) was done from base line ,4 weeks, 8weeks after injection.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <primary_completion_date type="Anticipated">February 2016</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>visual acuity</measure>
    <time_frame>until 6 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>central subfield thickness(CCT)</measure>
    <time_frame>until 6 month</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">133</enrollment>
  <condition>Diabetic Macular Edema</condition>
  <arm_group>
    <arm_group_label>Injection intravitreous bevacizumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Injection intravitreous bevacizumab at a dose 1.25mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Injection ziv-aflibercept at dose of 1.25 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Injection ziv-aflibercept at dose of 1.25 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Injection ziv-aflibercept at dose of 2.5 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Injection ziv-aflibercept at dose of 2.5 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
    <description>1.25 mg of bevacizumab is injected</description>
    <arm_group_label>Injection intravitreous bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ziv-aflibercept 1.25 mg</intervention_name>
    <description>1.25 mg of ziv-aflibercept is injected</description>
    <arm_group_label>Injection ziv-aflibercept at dose of 1.25 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ziv-aflibercept 2.5mg</intervention_name>
    <description>2.5 mg of ziv-aflibercept is injected</description>
    <arm_group_label>Injection ziv-aflibercept at dose of 2.5 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient at least 18 years old had type 1 or 2 diabetes who presented with Central
             DME involvement (defined as retinal thickening involving 1mm central sub field
             thickness(CCT)

          -  Have at least a BCVA ( best corrected visual acuity) between 20/50 to 20/320 Snellen
             equivalent

          -  Have received to anti-VEGF( anti -vascular endothelial growth factor) and laser
             treatment within the previous 3 months

        Exclusion Criteria:

          -  Uncontrolled glaucoma/uncontrolled diabet , high risk PRP(pan-retinal
             photocoagulation), one eye

          -  Prior treatment with intravitreal or peribulbar injection and laser therapy during the
             last 3 months

          -  Substantial cataract, history of uveitis

          -  Macular edema due to a cause other than DME

          -  VMT(Vitreomacular traction ) and ERM (epiretinal membrane)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Masoud Soheilian, MD</last_name>
    <phone>009822591616</phone>
    <email>labbafi@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Islamic Republic of Iran</name>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Masoud Soheilian, MD</last_name>
      <phone>009822591616</phone>
      <email>labbafi@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 2, 2016</study_first_submitted>
  <study_first_submitted_qc>January 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 5, 2016</study_first_posted>
  <last_update_submitted>January 4, 2016</last_update_submitted>
  <last_update_submitted_qc>January 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shahid Beheshti University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Zahra Rabbani Khah</investigator_full_name>
    <investigator_title>Assistant Professor of Ophthalmology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edema</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

